CDC Expands Recommendations for Pfizer-BioNTech and Moderna COVID-19 Vaccines Booster Doses
Recipients who completed an mRNA primary series (Pfizer-BioNTech or Moderna):
- People aged ≥50 years and residents aged ≥18 years in long-term care settings should receive a single COVID-19 vaccine booster dose (Pfizer-BioNTech, Moderna, or Janssen) ≥6 months after completion of their primary mRNA vaccine series.
- All other persons aged ≥18 years may receive a single COVID-19 vaccine booster dose (Pfizer-BioNTech, Moderna, or Janssen) ≥6 months after completion of their primary mRNA vaccine series based on their individual benefits and risks.
- Currently, a booster dose is not recommended in people aged <18 years.
Existing Guidelines:
- Individuals ≥18 years who received a dose of Janssen COVID-19 vaccine should receive a single COVID-19 vaccine booster ≥2 months or more after their first Janssen primary dose.
- Moderately or severely immunocompromised persons aged ≥12 years (Pfizer-BioNTech recipients) or ≥18 years (Moderna recipients) should receive an additional primary dose of the same mRNA COVID-19 vaccine administered for the primary series ≥28 days after completion of the initial 2-dose series. They are subsequently eligible for a booster dose 6 months after the 3rd (additional) dose.
The FDA Emergency Use Authorization (EUA) allows for the use of any FDA-authorized or -approved COVID-19 vaccine (Pfizer-BioNTech, Moderna, Janssen) as a heterologous (mix and match) booster dose in individuals following completion of their primary vaccination. Dosing interval for a heterologous booster dose is 6 months after a primary mRNA series or at least 2 months after a Janssen primary vaccine.
Resources
Interim Clinical Considerations for COVID-19 Vaccines
Considerations for use of a COVID-19 booster
Booster webpage for the public
|
